Answers are grounded in this paper and cite their sources.
Reveals FXR regulation of bile acid, lipid, and glucose pathways, indicating therapeutic potential for metabolic diseases.
Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, has been shown to be important in controlling numerous metabolic pathways; these include roles in maintaining bile acid, lipid and glucose homeostasis, in preventing intestinal bacterial infection and gallstone formation and in modulating liver regeneration and tumorigenesis. The accumulating data suggest that FXR may be a pharmaceutical target for the treatment of certain metabolic diseases.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: